Search

Displaying results 4041 - 4050 of 10000 in total
  1. Drug

    Bentoquatam

    go.drugbank.com/drugs/DB00516
    Approved

    Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak. … Bentoquatam contains bentonite, a clay, and is only effective as long as the film is visible on the skin.

  2. Drug

    Etavopivat

    go.drugbank.com/drugs/DB18176
    Investigational

    Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.

  3. Drug

    BHV-1300

    go.drugbank.com/drugs/DB22673
    Investigational

    BHV-1300 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  4. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    The oral polio vaccine (OPV) is a live attenuated vaccine containing a mixture of one or more strains of poliovirus serotypes. … After administration, OPV strains extensively multiply in the intestinal tract, becoming widely spread in the community to immunize a sizable proportion of those unvaccinated in the population[A220163]

  5. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. … TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Cambinol

    go.drugbank.com/drugs/DB15493
    Experimental

    Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.

  7. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue. … Regarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties.

  8. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate. … Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria.

  9. Drug

    Modipafant

    go.drugbank.com/drugs/DB16237
    Investigational

    Modipafant is under investigation in clinical trial NCT02569827 (Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore).

  10. Drug

    Meglumine

    go.drugbank.com/drugs/DB09415
    ApprovedInvestigational

    Synonyms: N-methyl-D-glucamineCategories: Compounds used in a research, industrial, or household setting